Aligos Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
Stockholders’ Equity (Deficit)
| Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income | Equity (Deficit) | |
| Balance as of December 31, 2023 | 3,003,855 | $7 | $578,325 | $(486,797) | $545 | $92,080 |
| Issuance of common stock related to ESPP purchase | 32,958 | - | 436 | - | - | 436 |
| Issuance of common stock upon exercise of pre-funded warrants | 800,613 | 1 | 2 | - | - | 3 |
| Issuance of common stock upon exercise of common warrants | 22,024 | - | 1,361 | - | - | 1,361 |
| Issuance of common stock from RSU vesting | 4,986 | - | - | - | - | - |
| Stock-based compensation expense related to employee stock awards | - | - | 7,948 | - | - | 7,948 |
| Stock-based compensation expense related to employee stock purchases | - | - | 504 | - | - | 504 |
| Other comprehensive loss | - | - | - | - | (94) | (94) |
| Net loss | - | - | - | (131,211) | - | (131,211) |
| Balance as of December 31, 2024 | 3,864,436 | $8 | $588,576 | $(618,008) | $451 | $(28,973) |
| Issuance of common stock related to ESPP purchase | 61,121 | - | 304 | - | - | 304 |
| Issuance of common stock upon exercise of pre-funded warrants | 146,468 | - | - | - | - | - |
| Issuance of common stock upon exercise of common warrants | - | - | - | - | - | - |
| Issuance of common stock from RSU vesting | 2,898 | - | - | - | - | - |
| Issuance of common stock upon PIPE | 2,103,307 | 1 | 105,003 | - | - | 105,004 |
| Issuance costs | - | - | (3,658) | - | - | (3,658) |
| Stock-based compensation expense related to employee stock awards | - | - | 4,541 | - | - | 4,541 |
| Stock-based compensation expense related to employee stock purchases | - | - | 503 | - | - | 503 |
| Other comprehensive income | - | - | - | - | 17 | 17 |
| Net loss | - | - | - | (24,193) | - | (24,193) |
| Balance as of December 31, 2025 | 6,178,230 | 9 | 695,269 | (642,201) | 468 | 53,545 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.